Association of Direct-to-Consumer Advertising of Prescription Drugs With Consumer Health-Related Intentions, Beliefs

JAMA Health Forum

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, AUGUST 12, 2022

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2022.2570?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=081222

About JAMA Health Forum: JAMA Health Forum has transitioned from an information channel to an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

 

About The Study: Researchers examined the association of direct-to-consumer advertising of prescription drugs with consumer intentions and beliefs related to prescription drugs and health-related behaviors in this study that included 2,874 individuals at risk of cardiovascular disease.

Authors: Matthew D. Eisenberg, Ph.D., of the Johns Hopkins Bloomberg School of Public Health in Baltimore, is the corresponding author.

 

(doi:10.1001/jamahealthforum.2022.2570)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.